The Congenital Heart Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Congenital Heart Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Congenital Heart Disease. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Congenital Heart Disease and features dormant and discontinued products.

GlobalData tracks nine drugs in development for Congenital Heart Disease by nine companies/universities/institutes. The top development phase for Congenital Heart Disease is phase ii with three drugs in that stage. The Congenital Heart Disease pipeline has nine drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Congenital Heart Disease pipeline products market are: PLx Pharma Winddown, Capricor Therapeutics and Mesoblast.

The key targets in the Congenital Heart Disease pipeline products market include Prostaglandin G/H Synthase 1 (Cyclooxygenase 1 or COX1 or Prostaglandin Endoperoxide Synthase 1 or Prostaglandin H2 Synthase 1 or PTGS1 or EC 1.14.99.1), Prostaglandin G/H Synthase 2 (Cyclooxygenase 2 or COX2 or Prostaglandin Endoperoxide Synthase 2 or PHS II or Prostaglandin H2 Synthase 2 or PTGS2 or EC 1.14.99.1), and Coagulation Factor X (Stuart Prower Factor or Stuart Factor or F10 or EC 3.4.21.6).

The key mechanisms of action in the Congenital Heart Disease pipeline product include Prostaglandin G/H Synthase 1 (Cyclooxygenase 1 or COX1 or Prostaglandin Endoperoxide Synthase 1 or Prostaglandin H2 Synthase 1 or PTGS1 or EC 1.14.99.1) Inhibitor with two drugs in Phase II. The Congenital Heart Disease pipeline products include five routes of administration with the top ROA being Oral and three key molecule types in the Congenital Heart Disease pipeline products market including Cell Therapy, and Small Molecule.

Congenital Heart Disease overview

Congenital heart disease is an impairment of the heart’s structure that is present at birth. It may change the normal flow of blood through the heart. It is the most common type of birth defect, occurring in about 1% of live births in the US. There are different types of congenital heart defects; the most common involve the inside walls of the heart, the valves of the heart, or the large blood vessels that carry blood to and from the heart. Some defects are simple and require no treatment, while others are critical and require treatment soon after birth.

For a complete picture of Congenital Heart Disease’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.